Shift from AstraZeneca and Long-Term Adaptation of Grünenthal
AstraZeneca (AZ) does not need an introduction. This global, science-led biopharmaceutical company has earned a positive reputation for the discovery, development, and production of prescription medicines of high-quality. It used to be the official developer and distributor of Crestor. On the 1st of December 2020, the company announced its decision to sell the rights to Grünenthal in more than 30 European countries. Thus, AZ has kept the right to distribute Crestor in 70 countries across the world that include North America, Japan, China, and other growing marke
On the 10th of February 2021, the agreement was achieved. The new contract supports the management of mature medicines that enables innovative treatments to all patients. Grünenthal has earlier received the rights to several established AZ medicines so that it has an experience of managing satin drugs and distributing them for European customers. But it does not mean that transformation will not be 100% smooth. AZ will keep manufacturing and applying Crestor to Grünenthal during the transition period. This will allow the new owner to acquire the required expertise and adjust its physical and marketing capabilities to the new product. At the same time, the long-term transformation will be less dramatic for patients. By the end of 2022, the transformation is about to be completed.
Crestor has taken the 101st rank among the most popular drug brands in the world. No wonder it attracts so much attention from researchers, medicals, and patients. The Crestor market keeps growing, so does its functionality. Although its features still have not been fully revealed, its medical value can hardly be denied. The future trends demonstrate the prospects of Crestor as the effective and many-sided statin drug. Its application has all the chances to become more diverse by covering new spheres of medical treatment.